Levels of Soluble Advanced Glycation End Product-Receptors and Other Soluble Serum Markers as Indicators of Diabetic Neuropathy in the Foot
Levels of Soluble Advanced Glycation End Product-Receptors and Other Soluble Serum Markers as Indicators of Diabetic Neuropathy in the Foot
复制标题
DOI：
10.2130/jim.0b013e318231db64
复制
发表时间：
2011-12-01
影响因子：
2.6
通讯作者：
Reda, Ahmed M.
中科院分区：
文献类型：
--
作者：
El-Mesallamy, Hala O.;Hamdy, Nadia M.;Reda, Ahmed M.
目的：糖基化终末产物（AGEs）及其受体（AGEs）的相互作用在糖尿病足（DF）并发神经病变的发病机制中起重要作用。我们的研究探讨了不对称二甲基精氨酸（ADMA），果糖胺，一氧化氮（NO）和可溶性（S）精氨酸水平之间的关系，在糖尿病患者和无神经病变。采用化学法或酶联免疫吸附法检测60例超重/肥胖2型糖尿病（T2 DM）患者循环中ADMA、果糖胺、NO和sIgA水平（体重指数30.5 ± 1.5 kg/m2）男性患者和20名年龄匹配（55 ± 3岁）的肥胖健康受试者作为对照组。T2 DM受试者被归类为无DF的患者（n = 30），其余为伴有神经病变的DF患者。（1656.6 [1198.8-2065.4] vs 1111.7 [909-1605.3] pg/mL; P < 0.05）。然而，DF组（1049.6 [783.7-1221.8] pg/mL）的水平与两组相比显著降低（P <0.05）。然而，糖尿病合并DF患者的ADMA和果糖胺显著高于不伴DF的T2 DM和健康对照组。此外，糖尿病患者的NO水平显著低于无糖尿病的糖尿病患者和对照组（分别为5 +/- 0.4和8 +/- 0.4 vs 42 +/- 2.5 μ mol/L; P < 0.05）。结论：可溶性糖基化终产物受体可能是DF发生的内源性保护因子，对DF的治疗有一定的价值。
Objective: Advanced glycation end products (AGEs) and the interaction with their receptors (RAGE) play an important role in the pathogenesis of diabetic foot (DF) associated with diabetic neuropathy. Our study examined the association between asymmetric dimethyl arginine (ADMA), fructosamine, nitric oxide (NO), and soluble (s) RAGE levels in serum of diabetic patients with and without neuropathy.Methods: Circulating levels of ADMA, fructosamine, NO, and sRAGE, estimated either chemically or by enzyme-linked immunosorbent assay, were examined in 60 type 2 diabetes mellitus (T2DM) overweight/obese (body mass index, 30.5 +/- 1.5 kg/m(2)) male patients and 20 age-matched (55 +/- 3 years) obese healthy subjects as control group. The T2DM subjects were categorized as patients without DF (n = 30), and the remaining were patients with DF associated with neuropathy.Results: First sRAGE levels were significantly increased in T2DM patients without DF in comparison to healthy controls (1656.6 [1198.8-2065.4] vs 1111.7 [909-1605.3] pg/mL, respectively; P < 0.05). However, in the DF group (1049.6 [783.7-1221.8] pg/mL), its level decreased significantly in comparison to both groups (P G 0.05). However, ADMA and fructosamine were significantly higher in diabetic patients with DF than both T2DM without DF and healthy controls. Moreover, NO was significantly lower in DF than in diabetic patients without DF and controls (5 +/- 0.4 and 8 +/- 0.4 vs 42 +/- 2.5 mu mol/L, respectively; P < 0.05). Finally, sRAGE levels were significantly correlated with ADMA, fructosamine, and NO.Conclusions: Soluble forms of the receptor for advanced glycation end product could be an endogenous protection factor against occurrence of DF, hence may be of therapeutic value in the treatment of DF.